Respiratory Syncytial Virus Epidemiology Forecast 2026-2035

Respiratory syncytial virus (RSV) is a leading cause of acute lower respiratory infections globally, particularly among young children. As per You Li et al., 2022, there were approximately 33.0 million RSV-associated episodes and 101,400 deaths worldwide in 2019 among children aged 0-60 months. According to the respiratory syncytial virus epidemiology forecast, RSV continues to pose a significant global health burden.

Respiratory Syncytial Virus Epidemiology Forecast Report Coverage

The analyst's “Respiratory Syncytial Virus Epidemiology Forecast Report 2026-2035” offers comprehensive information on the prevalence and demographics of respiratory syncytial virus. It projects the future incidence and prevalence rates of respiratory syncytial virus cases across various populations. The study covers age, gender, and type as major determinants of the respiratory syncytial virus population. The report highlights patterns in the prevalence of respiratory syncytial virus over time and projects future trends based on multiple variables.

The report provides a comprehensive overview of the disease, as well as historical and projected data on the epidemiology of respiratory syncytial virus in the 8 major markets.

Regions Covered

• The United States
• Germany
• France
• Italy
• Spain
• The United Kingdom
• Japan
• India

Respiratory Syncytial Virus Understanding: Disease Overview

Respiratory syncytial virus (RSV) is a highly contagious viral infection that primarily affects the respiratory tract, especially in infants, young children, older adults, and immunocompromised individuals. It is caused by the Respiratory Syncytial Virus, which spreads through respiratory droplets, direct contact, or contaminated surfaces. The virus infects the epithelial cells of the airways, leading to inflammation and mucus production. RSV commonly results in conditions such as bronchiolitis and pneumonia. It is broadly classified into two subtypes, RSV-A and RSV-B, with RSV-A generally associated with more severe outbreaks and clinical manifestations.

Respiratory Syncytial Virus Epidemiology Perspective

The respiratory syncytial virus epidemiology division offers information on the patient pool from history to the present as well as the projected trend for each of the 8 major markets. The analyst provides both current and predicted trends for the respiratory syncytial virus epidemiology scenario by examining a wide range of studies. Additionally, the report covers the diagnosed patient pool for respiratory syncytial virus and their trends. The data is broken down into specific categories, such as total prevalent cases in males and females, and total diagnosed cases across different age groups and patient pools.

• According to the World Health Organization, respiratory syncytial virus causes approximately 3.6 million hospitalizations and around 100,000 deaths annually among children under five years globally, with nearly half of deaths occurring in infants below six months, especially in low- and middle-income countries.
• As per Tom Wilkinson et al., 2023, in the United Kingdom, RSV led to about 29,160 hospitalizations and 83 deaths annually among individuals aged 0-17 years, with the highest burden concentrated in infants younger than six months of age.
• As per Erika Uusitupa et al., 2026, hospitalization rates among children under five years were higher in boys (4.0 per 1000) than girls (3.3 per 1000), with the largest gender disparity observed in children aged 3 to 23 months.
• According to Moussa Issa et al., 2025, RSV prevalence in Africa was estimated at 13.03% with an incidence of 3 per 1000 person-years, significantly higher in children and hospitalized individuals compared to the general population and nonhospitalized cases.
• According to the World Health Organization and supporting studies, RSV burden in adults is also substantial, with up to 160,000 hospitalizations and 10,000 deaths annually among older adults in the United States, particularly affecting those aged 65 years and above.

Country-wise Respiratory Syncytial Virus Epidemiology

The respiratory syncytial virus epidemiology data and findings for the United States, Germany, Spain, Italy, France, the United Kingdom, Japan, and India are also provided in the epidemiology section.

Across the covered regions, respiratory syncytial virus (RSV) epidemiology shows notable variability in incidence and surveillance coverage. As per Paolo Manzoni et al., 2025, Italy reports an RSV positivity prevalence of 4.5% in adults and 11.5% in immunocompromised populations, with around 26,000 annual hospitalizations and 1,800 deaths among those aged ≥60 years. According to Jessy Joseph et al., 2025, India demonstrates wide variability in RSV positivity (2.1%-62.4%), with surveillance data indicating 5% and 8.2% detection in acute respiratory infection and severe acute respiratory infection cases, respectively, reflecting demographic and methodological differences; similar structured surveillance efforts across Europe and Japan further highlight regional heterogeneity in RSV burden.

Respiratory Syncytial Virus: Treatment Overview

Respiratory syncytial virus infection treatment is mainly supportive, as there is no specific antiviral therapy widely recommended for routine use. Management focuses on relieving symptoms and maintaining adequate oxygenation and hydration. Mild cases are treated with rest, fluids, and antipyretics, while severe cases may require hospitalization, oxygen therapy, or mechanical ventilation. In high-risk populations, such as premature infants, monoclonal antibody prophylaxis (e.g., palivizumab) may be used to prevent infection. Emerging antiviral agents and vaccines are under development, aiming to reduce disease severity and transmission rates.

Key Questions Answered

• What are the key findings of respiratory syncytial virus epidemiology in the 8 major markets?
• What will be the total number of patients with respiratory syncytial virus across the 8 major markets during the forecast period?
• What was the country-wise respiratory syncytial virus epidemiology scenario in the 8 major markets in the historical period?
• Which country will have the highest number of respiratory syncytial virus patients during the forecast period of 2026-2035?
• Which key factors would influence the shift in the patient population of respiratory syncytial virus during the forecast period of 2026-2035?
• What are the currently available treatments for respiratory syncytial virus?
• What are the disease risks, signs, symptoms, and unmet needs of respiratory syncytial virus?

Scope of the Respiratory Syncytial Virus Epidemiology Report

• The report covers a detailed analysis of signs and symptoms, causes, risk factors, pathophysiology, diagnosis, treatment options, and classification/types of respiratory syncytial virus based on several factors.
• Respiratory Syncytial Virus Epidemiology Forecast Report covers data for the eight major markets (the US, France, Germany, Italy, Spain, the UK, Japan, and India).
• The respiratory syncytial virus report helps to identify the patient population, and the unmet needs are highlighted along with an assessment of the disease's risk and burden.